<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209729</url>
  </required_header>
  <id_info>
    <org_study_id>HGCSG0502</org_study_id>
    <secondary_id>DS-Elderly</secondary_id>
    <nct_id>NCT00209729</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.</brief_title>
  <official_title>Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hokkaido Gastrointestinal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hokkaido University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hokkaido Gastrointestinal Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the usefulness of Docetaxel plus S-1 combination chemotherapy based on the
      antitumor effect and survival period by performing a phase I/II study of this combination in
      Elderly patients with inoperable or with postoperative gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter Open-label, single-arm, phase I/II clinical trial is conducted on Elderly
      patients with histological stage IV gastric cancer given Docetaxel plus S-1. The usefulness
      of this regimens as 1st line therapy for gastric cancer was evaluated by the disease-free
      survival rate (DFR), overall survival rate (OS), incidence and severity of adverse event.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Registration is less
  </why_stopped>
  <start_date>April 2005</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the clinical response rate of patients in Phase I setting.</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the OS(Overall Survival) and DFS(Disease Free Survival).</measure>
    <time_frame>2-years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel plus S-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere</intervention_name>
    <description>X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Docetaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-1</intervention_name>
    <description>Day 1-14, P.O. everyday</description>
    <arm_group_label>1</arm_group_label>
    <other_name>S-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological diagnosis of gastric adenocarcinoma.

          2. Measurable or assessable lesions(Except for Phase I).

          3. Age: 76 ~ 80 years.

          4. Performance Status (ECOG): 0 ~ 2.

          5. No prior chemotherapy or only one regimen of previous chemotherapy (with a washout
             period &gt;4 weeks after the final day of the previous therapy). Adjuvant chemotherapy is
             not defined as previous therapy.

          6. No history of treatment with Docetaxel or S-1.

          7. No history of radiotherapy to the abdomen.

          8. Oral intake of S-1 is possible.

          9. Adequate function of major organs (bone marrow, heart, lungs, liver etc.). WBC
             3,500/mm3 and 12,000/mm3. Hb 10.0 g/dl. Platelet count 100,000/mm3. GOT and GPT 2.5
             times the upper limit of normal (excluding liver metastasis). T-Bil 2.0mg/dl.
             Creatinine &lt;1.5 mg/dl (but if it is 1.0 ~ 1.5 mg/dl, the dose of S-1 can be decreased
             according to the dose reduction criteria to allow registration in the trial). Normal
             ECG (not considering clinically unimportant arrhythmias and ischemic changes).

         10. Predicted survival for &gt;3 months.

         11. Able to give written informed consent.

        Exclusion Criteria:

          1. Severe pleural effusion or ascites.

          2. Metastasis to the central nervous system (CNS).

          3. Active gastrointestinal bleeding.

          4. Active infection.

          5. Diarrhea (watery stools).

          6. Uncontrolled ischemic heart disease.

          7. Serious complications (such as intestinal paralysis, intestinal obstruction,
             interstitial pneumonia or pulmonary fibrosis, uncontrolled diabetes mellitus, heart
             failure, renal failure, or hepatic failure).

          8. Active multiple cancer.

          9. Severe mental disorder.

         10. Pregnancy, possible pregnancy, or breast-feeding.

         11. Flucytosine treatment.

         12. Judged to be ineligible for this protocol by the attending physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>76 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masahiro Asaka, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hokkaido Gastrointestinal Cancer Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hokkaido University Hospital (Hokkaido University Graduate School of Medicine)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8638</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>May 24, 2010</last_update_submitted>
  <last_update_submitted_qc>May 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yoshito Komatsu / A vice-director, Associate Prof.</name_title>
    <organization>Hokkaido University Hospital Cancer Center</organization>
  </responsible_party>
  <keyword>Docetaxel</keyword>
  <keyword>S-1</keyword>
  <keyword>Elderly Patients</keyword>
  <keyword>Gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

